The content is available as a PDF (126.6 KB).
editorial . 2014 Apr 1;10(4):813–814. doi: 10.4161/hv.29049
Letter from the Editor
Ronald W Ellis
1,*, Eva M Riedmann
2
Ronald W Ellis
1Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel
Find articles by Ronald W Ellis
Eva M Riedmann
2Acquisitions Editor; Landes Bioscience; Vienna, Austria
Find articles by Eva M Riedmann
1Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel
2Acquisitions Editor; Landes Bioscience; Vienna, Austria
*
Correspondence to: Ronald W. Ellis, rellis@landesbioscience.com
Received 2014 Mar 22; Accepted 2014 Mar 22; Collection date 2014 Apr.
Copyright © 2014 Landes Bioscience
This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
PMCID: PMC4896567 PMID: 24784356